Pancreatic alpha-amylase (HPA) (HPA)

Human pancreatic alpha-amylase (HPA) is a calcium-dependent hydrolase secreted by the pancreas that initiates the digestion of dietary starch by cleaving alpha-1,4-glycosidic bonds (UniProt P04746). This enzymatic activity produces maltose, maltotriose, and alpha-limit dextrins, which are subsequently broken down into glucose for absorption in the small intestine (NCBI Gene ID: 279). As a primary regulator of starch-derived glucose entry into the blood, HPA is a significant therapeutic target for treating type 2 diabetes and obesity (PubMed PMID: 22035012). Inhibition of HPA slows the rate of carbohydrate digestion, effectively reducing postprandial blood glucose spikes. Drugs such as acarbose act as competitive inhibitors of HPA, although their clinical utility is sometimes hampered by gastrointestinal side effects like flatulence and diarrhea caused by the fermentation of undigested starch in the large intestine (StatPearls: Pancreatic Enzymes). Additionally, measuring serum HPA levels is a standard clinical practice for diagnosing acute pancreatitis and monitoring pancreatic function (Mayo Clinic Laboratories). Research into novel HPA inhibitors continues to focus on improving potency and reducing the side effect profile associated with current starch-blocker therapies (Journal of Medicinal Chemistry).

Other names

Alpha-amylase 2A1,4-alpha-D-glucan glucanohydrolaseAMY2AAMY2Human pancreatic alpha-amylase

Competitive inhibition of the alpha-amylase enzyme to delay the hydrolysis of complex carbohydrates into absorbable monosaccharides, thereby lowering postprandial glucose levels.